Astrazeneca (AZN) Receivables Refunds (2016 - 2025)
Astrazeneca (AZN) has 3 years of Receivables Refunds data on record, last reported at $1.2 billion in Q4 2025.
- For Q4 2025, Receivables Refunds fell 37.71% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, down 37.71%, while the annual FY2025 figure was $1.2 billion, 37.71% down from the prior year.
- Receivables Refunds reached $1.2 billion in Q4 2025 per AZN's latest filing, down from $1.9 billion in the prior quarter.
- Across five years, Receivables Refunds topped out at $1.9 billion in Q4 2024 and bottomed at $1.2 billion in Q4 2025.
- Average Receivables Refunds over 3 years is $1.5 billion, with a median of $1.4 billion recorded in 2023.
- Peak YoY movement for Receivables Refunds: soared 30.36% in 2024, then plummeted 37.71% in 2025.
- A 3-year view of Receivables Refunds shows it stood at $1.4 billion in 2023, then skyrocketed by 30.36% to $1.9 billion in 2024, then plummeted by 37.71% to $1.2 billion in 2025.
- Per Business Quant database, its latest 3 readings for Receivables Refunds were $1.2 billion in Q4 2025, $1.9 billion in Q4 2024, and $1.4 billion in Q4 2023.